Your browser doesn't support javascript.
loading
Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.
Liu, Yunqing; Yan, Dejun; Yang, Lin; Chen, Xian; Hu, Chun; Chen, Meilan.
Affiliation
  • Liu Y; Key Laboratory of Brain, Cognition and Education Sciences, South China Normal University, Ministry of Education, Guangzhou, China.
  • Yan D; Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, 510631, China.
  • Yang L; Key Laboratory of Brain, Cognition and Education Sciences, South China Normal University, Ministry of Education, Guangzhou, China.
  • Chen X; Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, 510631, China.
  • Hu C; Department of Anesthesiology, the Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
  • Chen M; Rehabilitation Medicine Institute of Panyu District, Guangzhou, 511499, China.
Transl Neurodegener ; 13(1): 20, 2024 Apr 11.
Article in En | MEDLINE | ID: mdl-38600555
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stathmin / TDP-43 Proteinopathies / Amyotrophic Lateral Sclerosis Limits: Humans Language: En Journal: Transl Neurodegener / Translational neurodegeneration Year: 2024 Document type: Article Affiliation country: China Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stathmin / TDP-43 Proteinopathies / Amyotrophic Lateral Sclerosis Limits: Humans Language: En Journal: Transl Neurodegener / Translational neurodegeneration Year: 2024 Document type: Article Affiliation country: China Country of publication: United kingdom